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Based on a survey of the French Biotech SMEs (see annex 1), this article examines 
localisation effects in the biotechnology sector. It consists of two strands of analysis. 
The first presents a detailed statistical survey of the French biotechnology sector. 
Among other things, the survey shows that a) localisation effects within France are 
strong, and b) French firms can be grouped into four general types of firm, ranging from 
‘type 1’ growth-oriented product firms, to ‘type 2’ niche market players, ‘type 3’ 
subsidiaries of larger firms, and ‘type 4’ firms that have been acquired. Localisation 
effects differ across these firms, especially across type 1 (international) and type 2 (very 
localised) firms. The second strand of analysis consists of a review of the localisation 
and related cluster literature, with implications identified for localisation and knowledge 
spillovers within biotech clusters. The relative effects of the proximity of scientific 





Biotechnology can be defined as a set of techniques and knowledge which are related to 
the use of living organisms in production processes and are the outcome of recent 
advances in molecular biology (Ducos and Joly 1988). The division of work is at the 
centre of research on the economics of innovation which accounts for the dynamics of 
biotechnological knowledge. Each new breakthrough opens onto new hypotheses and 






































competencies, in a process of cumulative discovery. Within this process, academics 
perform basic research, SMEs explore these new fields of knowledge, and corporations 
exploit them industrially and commercially (Orsenigo et al. 1998, Sharp 1999). Our 
objective is to analyse the role of geographic proximity in the development of those 
SMEs. The creation and growth of biotech start-ups and, more generally, high-tech 
firms, has resulted in the formation of clusters in both the US and Europe (Feldman 
1994, Prevezer 1998, Swann 1999). 
Research on the development of biotechnology, carried out in areas of the economics of 
innovation and the geography of innovation, is based primarily on cases in the US rather 
than in Europe. For France, a recent study can be used to draw up a typology of new 
biotech firms (Lemarié et al. 2000 a), thus completing the overview by Ernst & Young 
(Ernst & Young, 2000). This study shows that on 1 January 1999 France had just over 
400 biotechnology SMEs employing 15,000 people, with an estimated turnover of 
thirteen billion francs. Estimates based on the survey initiated by the French ministry 
for education, research and technology are consistent with the information published by 
Ernst & Young, although they indicate a higher number of firms in France. The average 
size in terms of the number of employees is nevertheless similar (about forty persons). 
The majority as founded after 1990 (70 per cent of the sample). Most of the recent firms 
aim for the pharmaceutical sector. The second sector in terms of the number of firms 
and employees is agriculture and the agro-food sector. Firms involved in ag-biotech are 
older than those which aim for the pharmaceutical sector (Lemarié et al. 2000 a). 
Most of these new biotech firms were created in the Ile-de-France region, especially at 






































etc.). From this point of view, the French case resembles the US experience. In the US 
the biotechnology sector has developed around centres of scientific excellence (Zucker 
and Darby 1996, Zucker, Darby and Armstrong, 1998), since the mobility of researchers 
from academic research centres towards the private sector is a vehicle for the diffusion 
of knowledge and a powerful incentive for start-ups. Is the constitution of clusters in 
France similar to the US? Are the determinants of biotechnology clusters in France the 
same as those identified for the US? A review of studies on the determinants of the 
clustering of productive activities and, more specifically, of innovation, will be 
proposed in the first part of this paper. The second part considers the French case in the 
light of these approaches. The role of institutions and the importance of the diversity of 
biotechnology firm models is then discussed in the third part. 
 
 
How can the clustering of new biotech firms be explained? 
 
Two main categories of analysis are usually applied, based on research conducted in the 









































Economic geography and geography of innovation. 
 
The first explanation is the one proposed by new economic geography (Fujita and 
Thisse 1997), introducing the possibility of conjoint localisation of firms in the same 
space (a town, for example, but rather a region or area of production in the case under 
consideration here), at the expense of neighbouring or rival spaces. The suggested 
causes of this polarisation are multiple but we can identify two particularly important 
ones leading to the establishment of localised increasing returns (Krugman 1991 a, 1991 
b) which maintain a divergent process of localisation of activities: the existence of 
indivisibilities and the preference for variety. Although the question of indivisibility is 
hardly relevant for small firms, the instrumentation involved in biotechnology can play 
a decisive part in the localisation of activities. A start-up cannot in vest in heavy 
equipment that it will use only occasionally. However, these studies focus only on 
pecuniary externalities, to the exclusion of technological externalities. For P. Krugman, 
‘knowledge flows are invisible, they leave no paper trail by which they may be 
measured and tracked.’ (Krugman 1991 a: 53) Or else, ‘by focusing on pecuniary 
externalities, we are able to make the analysis much more concrete than if we allowed 
external economies to arise in some invisible form. (This is particularly true when 
location is at issue: how far does a technological spillover spill?)’ (Krugman 1991 b: 
485). 
 
Unlike Krugman, Jaffe, Trajenberg and Henderson analyse pecuniary externalities and 






































they do leave a paper trail in the form of citations’ (Jaffe et al. 1993: 26). These three 
authors, as well as Almeida and Kogut, use patent citations to identify knowledge 
spillovers and their geographical dimension (Jaffe et al. 1993, Almdeida and Kogut 
1997). Two types of research can be differentiated in the latter type of approach 
(Feldman 1999).  
The first is to try to measure directly the impact of geographic proximity on 
technological spillovers, which are themselves supposed to enhance innovation 
performance. Proximity is modelled in terms of distance or geographical coincidence of 
research units inside the boundaries of a state or a metropolitan area. Despite differences 
in the modelling and identification of technological spillovers (the patent or innovation 
identified in the market), the econometric results of Feldman (1994), Audretsch and 
Feldman (1996a), Jaffe (1989) and Acs et al. (1994) all indicate that spillovers are 
favoured by geographic proximity (for a critical analysis, see Autant-Bernard and 
Massard 1999). 
 
In the US, biotech start-ups are localised near poles of academic excellence (Prevezer 
1998). More generally, innovation in a given region is closely related to public and 
private research spending in the region (Feldman 1994). There are no substitution 
effects between public and private R&D spending. They enhance each other to create 
areas of expertise (Jaffe et al. 1993). Venture capital companies also contribute to the 
growth of biotechnology clusters. Lerner shows that growth in the number of employees 
and the sales of start-ups is greater when they are located near venture capital 






































development of a flow of superior information (Lerner 1996). It is primarily regional 
public venture capitalists and above all ‘business angels’ that finance the early stages of 
SMEs. The main characteristics of these actors is that they are essentially local, they 
invest small sums and they establish very informal relationships with SMEs (Mason and 
Harrison 1995). 
 
The second strand of analysis focuses on the role of interactions as sources of 
knowledge transfers (Zucker et al. 1996, 1998; Almeida and Kogut 1997, Autant-
Bernard and Massard 2000). For Zucker et al., ideas are embodied in individuals who 
have the skills, knowledge and know-how to engage in technological progress. Their 
papers analyse the human capital of key individuals rather than the average human 
capital of the local labour market. Biotech start-ups are localised in regions in which 
this intellectual capital resides. These star scientists embody knowledge breakthrough 
techniques that are initially available only at the scientists’ laboratory, making it costly 
for other to obtain and use. These results suggest that the localisation of biotech start-
ups and their performance cannot be explained by the presence of universities but by the 
relationship between renowned academic researchers and biotech firms (Zucker et al. 
1998). Technological spillovers are no longer abstract, they can be traded (research 
contracts, licences, etc.). Consequently, the formal institutions that link inventors, 
capital and markets are important factors explaining the localisation of high-tech firms 








































The importance of geographic proximity in question 
 
But if geographic proximity is important for firms’ innovation, what are we actually 
talking about? For economic geography, geographic proximity is a physical distance 
between actors and is accompanied by transport costs. For the geography of innovation, 
it is related to the creation of tacit knowledge that firms assimilate. Geographic distance 
is not the only significant factor here. In order to understand it, it is useful to distinguish 
and define two concepts: geographic proximity and organisational proximity (Torre and 
Gilly 2000). 
 
Geographic proximity concerns spatial separation and relations in terms of distance. It 
consists of more than the reference to natural and physical constraints, clearly inscribed 
in its definition, since it also encompasses aspects of social construction, such as 
transport infrastructure, which impact on access time, or financial resources allowing 
for the use of certain communication technologies. Organisational proximity is based on 
two types of logic that can be qualified as similitude and affiliation, respectively. With 
the logic of affiliation, actors belonging to the same area of relations (firm, network, 
etc.), in which different kinds of interaction take place (e.g. co-operation or circulation 
of knowledge), are close in organisational terms. With the logic of similitude, actors 
who resemble one another, i. e. who possess the same area of reference and share the 
same knowledge, so that the institutional dimension is important, are close in 
organisational terms. In the first case, membership of the same set is conditioned by the 






































‘resemblance’ of representations and modes of functioning. Far from being antinomic, 
these two aspects can sometimes be reconciled, particularly when affiliation initially 
based on horizontal relations of an intra-industrial nature are subsequently concretised 
in an increase in interdependence between organisations, signifying greater similarity 
(or institutional proximity) between the players. In the case of biotechnology and many 
high-tech activities, it is the logic of affiliation that plays an important part, particularly 
in the circulation of knowledge between organisations – a circulation based on a mode 
of functioning similar to that of inter-individual relations. 
 
How can this distinction help us to understand high-tech clusters and, more specifically, 
those of biotechnology and their growth? First, incubators and facilities for assisting and 
supporting business creation play an essential role in the geography of localisation as 
presented in spatial economic models. The actors may be geographically close without 
any relations between them. They will take as much advantage as possible of pecuniary 
externalities. The localisation of R&D is then the result not of spillovers but of the 
localisation of production factors. For Simmie, the presence of skilled workers is the 
only local determinant of the innovative capacity of firms in the Herefordshire region 
(Simmie 1997). Another example is the numerous cases of failure of technology parks, 
technopoles, etc. which, it was hoped, would create ex nihilo a dynamic of collective 
innovation. Secondly, is this collective dynamic, if it does exist, strengthened or not by 
the specialisation of the cluster? Not all studies agree on this point. Yet for high-tech 
activities, unlike traditional activities, it seems that Jacobs-type externalities (diversity) 






































of towns (Paci and Usai 2000). Swann distinguishes the effects of localisation on the 
entry of new firms and on the growth of incumbents (Swann 1999, see also Prevezer 
1998). It appears that while the effect of own-sector strength on growth is positive, the 
effect on entry can be negative. The effect of other sectors on incumbent growth is 
negative (though often statistically insignificant), but (in contrast) the effect of other 
sectors on entry can be positive and fairly significant. But in biotechnology it is the 
strength of the science base in a cluster that is particularly important in influencing the 
amount of new entry, although there are a limited number of cross-sectoral effects 
attracting entry (Swann 1999: 116). 
 
While most of the studies cited highlight the correlation between the R&D efforts of 
firms or universities situated in the same area, this does not mean that location plays a 
particular part. Firms’ innovation can be affected as much by the R&D of firms or 
universities located in other regions (Autant-Bernard and Massard 1999). A study by 
Audretsch and Stephan (1996) on biotechnology in the US is illuminating in this 
respect. It shows that employment of local scientists varies considerably from town to 
town and from firm to firm. This seems to argue for a more detailed analysis of the 
characteristics of regions and firms. Their study also concludes that while the founders 
of firms set up near the university from which they graduated, the companies for which 
they work as scientific advisors are not essentially local. Finally, it shows that 70 per 
cent of formal relations between scientists and biotech firms are inter-city relations 







































Studies on relations between biotech firms and universities are not, however, 
transposable to the choice of location when firms set up. The analysis is very different 
at the time of start up, when the survival and development of the firm depend on the 
founder’s close network of relations, and later when the firm is established and builds 
sound relations in the same scientific, productive and commercial network. A number of 
studies illustrate the theory of decreasing importance of geographic proximity in the 
course of time. The localised character of externalities is explained by the tacit 
dimension of knowledge and its embodiment in certain persons (not all). Almeida and 
Kogut share this theory with Zucker et al. in a study of patents, their citation and the 
mobility of patent holders (Almeida and Kogut 1997, Jaffe et al. 1993, Audretsch and 
Feldman1996b). They claim that there is a substitution of geographic proximity by an 
organisational proximity detached from the locality. This theory of a natural tendency 
for knowledge to be codified must nevertheless be qualified. First, it is impossible to 
codify everything. Codification of existing knowledge paves the way for new 
combinations of knowledge and hence for new tacit knowledge (Senker 1995). 
Moreover, if the creation process is quick (thus, if the rate of technological 
obsolescence is high), it is not profitable to invest in codification. Lastly, expertise at 
the cutting edge of knowledge is not always mobilised in the same way by firms. 
Catherine and Corolleur, by analysing business models of biotech firms, show that, 
depending on their scientific ambition, SMEs will or will not mobilise scientific 








































Biotechnology clusters and biotech start-ups in France. 
 
Where are biotech start-ups located in France and why? How can biotech clusters be 
explained in the French case? What part have public institutions played in their 
emergence? Do all these firms mobilise the resources of their close geographical 
environment to the same extent? 
 
 
Biotech clusters in France, the importance of public institutions 
 
In France, the development of the biotechnology sector remains concentrated on a few 
leading regions, as shown in Graph 7.1. While Ile-de-France remains dominant, 
especially as regards firms created around universities and Genopole Evry, Alsace, 
Auvergne, Aquitaine, Bretagne, Rhône-Alpes and Midi-Pyrénées are also regions in 
which biotech firms set up. Firms specialising in genome and drug-development 
technologies are situated primarily in Ile-de-France, while firms in Aquitaine, Brittany 








































Graph 7.1: Percentage of biotech firms in each area (main regions) 
 











Source: Author’s Calculation 
 
 
Is the geography of new biotech firms related to public R&D externalities (are biotech 
SMEs set up in regions in which many researchers are present)? Graph 7.2 shows that 
the localisation of biotech start-ups is neither proportional to the number of researchers 
in academia in the region nor proportional to the global number of publications in the 
same area. A first explanation can be found in the specific nature of the French public 
research system compared to the US one. Unlike the US system, where relations 
between universities and local firms are particularly strong (Mansfield 1995), the 






































situated high upstream and the Paris-Province structure is dominant (Grossetti and Bès 
2000). Research contracts between the public and private sectors and business creation 
by researchers are in the minority. When they are present, public research externalities 
appear far more localised in the research phase and less in the innovation phase (Autant-
Bernard 2001).
4 Yet over 90 per cent of firms created by researchers are set up in the 
immediate environment of the laboratory for which they used to work (Grossetti and 
Bès 2000; and for biotechnology in France: Catherine and Corolleur 2000). Do clusters 
show a critical mass at which entry starts to take off rapidly? Swann considers that the 
take-off point for entry in most computer industry sectors is reached when total 
computer industry employment in the cluster is about 10,000 (Swann 1999). By 1985 
Ile-de-France had already grown beyond the critical mass but the other regions had not 
(Swann 1999.). A priori, one would expect the same to apply to biotechnology. But the 
regions with the highest proportion of new firms are Auvergne, Rhône-Alpes and Ile-
de-France, while firms in Alsace, Brittany and Centre are generally older. While Ile-de-














































Graph 7.2: Comparison between the number of biotech firms and the academic 
research potential, by region (main regions) 
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Source: Author’s Calculation 
 
 
Since geographic proximity seems important in the early phases of research (theory of 
the link between geographic proximity and the nature of the knowledge involved) and 
the growth of new start-ups does not strictly follow the ranking of regions, should an 
explanation for the dynamics of biotech clusters not be sought in the intervention of 
public actors (laws, innovation incentives, etc.)? P. Monsan (Monsan 2000) proposes an 
up-dated analysis of the recent history of government policy to support biotechnology. 
At the beginning of the 1980s the aim of French public support for biotechnology was 






































public funding was used to revitalise groups working in the life sciences and to bring 
them together, at the same time assisting them to rapidly integrate molecular biology 
and genetic engineering methodologies. To strengthen relations between public research 
and industry, biotechnology transfer centres were set up, for example in public sector 
research (PSR): Institut Pasteur, CNRS (Conseil National de la Recherche Scientifique), 
INRA (National Institute of Agronomic Research) etc. Subsequently, several of them 
became research innovation and technological centres (CRITTs, Centre Régional d’ 
Innovation et de Transfert de Technologie)). Lastly, national public policy in favour of 
biotech was also designed to support start-ups. A number of companies were created 
using venture capital. These include Transgene (founded in Strasbourg in 1979), 
Immunotech (Marseille 1982) and BioEurope (Toulouse 1984).  
 
After this initial phase, the major concern of public policy as it was redesigned in 1985 
was to preserve the transversal nature of biotechnology while concentrating funds on 
four priority domains: the food industry, health, IT and international relations. With a 
budget of 16.5 million Euros over three years, the ‘Expansion’ biotechnology 
programme largely funded small biotech companies created during the eighties, 
enabling them to boost their own research activity (most often within a close partnership 
with French state research establishments), and to accelerate the development of 
innovative products. But despite all these efforts, the biotechnology revolution 
announced at the beginning of the eighties was slow in coming, and the results of 
research already engaged, in terms of turnover and job creation, remained erratic. At the 






































groups’ research and development programmes, so as to accelerate the 
commercialisation of research through concrete action. This was the objective of the 
BioAvenir programme launched in 1991. In bringing together Rhône Poulenc and 
various public research establishments, BioAvenir constituted an innovative partnership 
between the private and public sectors. In the mid-90s national and regional public 
authorities launched new biotechnology programmes. Their aims were to reinforce the 
partnership between private and public research, and to encourage the creation of new 
growth companies by facilitating research scientists’ mobility between sectors and by 
creating facilities (technology platforms and incubators). This was a strong incentive to 
business creation, and at the time was backed up by renewed interest in biotechnology 
from the finance community, in particular for gene therapy, neuro-degenerative disease 
treatment and genomics. 1996 saw the arrival of the EASDAQ (European Association 
of Securities Dealers Automated Quotation), the European financial market for high 
growth high-tech companies, along with that of the Paris Bourse’s ‘Nouveau Marché’. 
Both factors contributed to the development of numerous biotech company creation 
projects. 
 
Different public policy tools have been mobilised at national and regional level. The 
effects of local public policy can be seen in very dynamic regions such as Auvergne, 
Alsace and Aquitaine where the science base appears to be weaker than in other regions 
(like Rhone Alpes, for example). As shown by Genet (1997), these regions have all 
invested in a technopole as an incentive for start-ups. The main public structures 






































Montpellier, Strasbourg, Paris (Institut Pasteur), Toulouse, Lille, Lyon-Grenoble, Aix-
Marseille and Bordeaux, with an annual budget of 10 million francs. To these can be 
added the incubators financed by the state and regions. The regional distribution of 
innovation incentives from ANVAR (Agence National de Valorisation de la Recherche) 
can be used as a (partial) indicator of differences in regional growth (Table 7.1). At this 
stage the public structures set up have been defined in such a way as to promote 
specialisation and complementarity on a national scale. Competition between public 
actors in clusters, to accommodate as many biotech start-ups as possible, is therefore 
likely to concern a territory-specific offering rather than an undifferentiated public 
offering (Corolleur and Pecqueur 1996). But while the strategy of public actors is to 
anchor as many firms as possible in the territory (i. e. to limit firms’ nomadism), some 
firms’ interest in a territory is limited to the availability of skilled workers at a low cost, 
while others seek local partners (laboratories, consultants in intellectual property rights, 










































Table 7.1 : Distribution of ANVAR aid by region in 1999 
  Number of projets  Total amount of ANVAR grants 
Ile-De-France 42  20%  20,4  23% 
Provence-Alpes-Côte-D'Azur 32  15%  13,2  15% 
Rhône-Alpes 23  11%  9,4  11% 
Auvergne 19  9%  9,2  10% 
Midi-Pyrénées 13  6%  5,1  6% 
Aquitaine 10  5%  2 2% 
Bretagne 8  4%  1,6  2% 
Languedoc-Rousillon 9 4%  4,4  5% 
Nord-Pas-De-Calais 8  4%  2,4  3% 
Pays de la Loire  8  4%  1,3  1% 
Alsace 7  3%  7,7  9% 
Limousin 6  3%  1,4  2% 
Picardie 7  3%  1,1  1% 
Centre 5  2%  2,2  2% 
Haute-Normandie 4  2% 1,8  2% 
Poitou-Charentes 5  2%  2,7  3% 
Basse-Normandie 2  1% 1,3  1% 
Bourgogne 3  1%  0,4  0% 
Lorraine 3  1%  1,3  1% 
Champagne-Ardenne 1  0%  0,2  0% 
   100%    100% 
Source: ANVAR 2000 Bilan sectoriel 1999, Pharmacie Biotechnologie, Paris, Direction de la Technologie ANVAR. 
 
Recently public policy supports business creation in the regions is recent. It has 
stimulated new business creation. However, the creation of economic wealth remains 








































Graph 7.3: Comparison of the number of firms and the turnover of those firms, by 
region 
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Source: Author’s Calculation 
 
 
Different trajectories on which geographic and organisational proximity have a 
differing impact 
 
Our study (Lemarié and Mangematin 2000) reveals one successful trajectory (Type 1), 
representing a minority of cases, and three more disparate trajectories. Some firms have 






































have existed for over ten years (Type 2); others are affiliated to a parent company (Type 
3); and, lastly, large industrial corporations (Type 4) have bought others out. These 
different business models do not mobilise local technico-economic resources equally. 
 
 
Type 1: Successful start-ups – a small minority of firms 
 
Twenty-eight firms in our sample (14.4 per cent of the 194 respondents), considered to 
be the flagships of the French biotechnology industry, have grown very fast. Active 
primarily in the fields of genome research and drug development, their main outlet is 
the pharmaceuticals market. Whether they were founded about ten years ago (eleven of 
them) or before 1980 (twelve of them – close to half), all of them have over fifty 
employees. Yet these firms employ less than a quarter of all employees in the 
biotechnology sector. Moreover, only eight of them (i.e. 4.1 per cent) have a turnover of 
more than 100MF (fifteen million Euros) and only six of those are listed on the stock 
exchange (Biodome, Cerep, Chemunex, Genset, Quantum Appligene, Transgène). 
Their development is based primarily on the presence of investors in national and 
international capital. Venture capital companies, present from the start, have been active 
in orientating these companies, setting them on a course of rapid growth. By extending 
the number of subscribers beyond the inner circle, firms are able to benefit from advice, 
contacts, human capital and an introduction into networks with which they are 
unfamiliar or which require too much effort to explore. (Fewer than 30 per cent of the 






































Moreover, quoting of the firm on the stock exchange enables venture-capital firms to 
sell their shares and withdraw their capital, an indispensable condition for the 
perpetuation of venture capital financing of biotechnology firms. The presence of 
venture-capital firms in these companies favours the development from essentially 
domestic organisational proximity (family capital, network of entrepreneurs) to 
organisational proximity with networks comprising all actors on the biotech scene.  
 
To maintain technological skills, fast-growing firms rely on collaboration with French 
or foreign universities and with public institutions such as the CNRS or INRA, rather 
than basing their development on a product–specific market combination. Collaboration 
with other firms, especially pharmaceutical companies, enables them to extract value 
from their technologies. Geographic proximity is clearly of little importance for this 
type of firm which is situated in an international market for the diffusion of its products, 
and maintains relations with laboratories situated elsewhere. On the other hand, the need 
to be connected to major communication axes shows the full importance of relations of 
organisational proximity and the crucial nature of introduction into networks of strong 
relations. Note, however, that these firms need to be close to centres of excellence to 
benefit from public research spillovers through interpersonal relations and international 
exchange maintained by academic laboratories. The quality of a firm’s interaction with 
players in the same geographic area will depend on scientific life in that environment. 
To attract the best researchers, PhDs and post-doctoral researchers – all potential 
collaborators –, firms are well advised to take advantage of neighbouring centres of 






































Type 2: Stable businesses in niches 
 
More than half (53.3 per cent) of biotech employees work in firms that have followed a 
different development trajectory to that of Type 1 firms. Founded in some instances in 
the 1970s, generally as limited liability companies (SARL) or limited companies (SA) 
with private persons only as shareholders, their turnover today is between ten MF (1.5 
million Euros) and 100MF (fifteen million Euros). These firms (e.g. Cayla and Anda 
Biologicals) employ between 10 and 50 people, derive a large share of their turnover 
from export and invest close to 25 per cent of their turnover in research. Active mainly 
in the pharmaceuticals market, they have a relatively broad technological base 
maintained both by internal research and by relations with French and foreign 
universities. These firms, which have been in existence for several years, do not seem to 
have the intention of becoming leaders in their field on a world wide scale; they 
nevertheless represent an alternative development trend for biotech companies. 
These companies are characterised by a strong reference to geographic proximity when 
they seek research or market resources in their immediate environment. In this case, 
relations with users of products and services are formed on the basis of geographic 
proximity. Yet they do not, for all that, neglect resources from organisational proximity, 








































Type 3: Firms affiliated to a parent company 
 
One of the strategies of pharmaceutical or seed companies is to create biotechnology 
firms, either alone or as a joint venture. Biotechnology is in fact a high-risk business 
whose development requires specific skills. Moreover, small structures are more 
flexible and easier to adapt to major changes triggered by the production of new 
scientific knowledge. Finally, investing in a biotechnology enterprise also enables firms 
to set up in a country with a view to taking advantage of its research "externalities" and 
of new markets. 
 
Thus, major French or foreign companies (e.g. Limagrain or Rhône Poulenc, and 
Monsanto, respectively) have invested in subsidiaries specialised in biotechnology, 
either to secure a foothold in France (e.g. BioSepra, Bachem Biochimie and Diagnostica 
Stago) or to separate biotechnology from the firm’s main business (e.g. Syral, Biosem 
and Limagrain Genetics). These firms, which benefit from the captive market 
represented by the parent company and from the network of markets to which the latter 
provides access, have a faster-increasing turnover than that of independent firms. It 
seems here that geographic proximity plays a relatively minor part in this type of 
strategy, based above all on the parent company’s internal network. Organisational 
proximity is the most important factor, for geographic incidence is related to location of 








































Type 4: Firms which are sold 
 
In the latter type of trajectory, firms are bought out by industrial groups after proving 
themselves. Included in this category are firms such as Appligene (founded in 1985, 
with an 80 per cent takeover by the US company Oncor in 1995, and Appligene Oncor 
then bought out in 1999 by the Canadian Quantum), Systemix (founded in 1988, bought 
out by Sandoz in 1992) and Agrogene (founded in 1989 and progressively bought out 
by Limagrain before takeover by Perking Elmer), which differ from subsidiaries created 
ex nihilo (Type 3) in so far as they are initially independent. Takeovers can be explained 
by problems encountered by some SMEs (difficulty in gaining access to the market, 
incomplete technological base) and by the purchaser’s intentions. The takeover must be 
considered as a step in the development of the SME and not as a sign of failure. The 
purchaser’s intention is either to complete its technological base by adding the SME’s 
portfolio of patents or technological competency, or to use the SME to facilitate its 
commercial growth. In the latter case, seldom mentioned, the purchaser is often a 
foreign group. The SME then acts as a bridgehead in France to transfer technologies or 
products developed by the parent company. 
A takeover generally leads to significant changes in biotech SMEs, for these firms were 
initially created to support an independent activity that ends up having to serve the 
interests of its main shareholder. If the SME was bought to be a bridgehead in Europe or 
France (e.g. Oncor’s takeover of Appligene or Perkin Elmer’s buy-out of Agrogene), its 
research activities will probably be scaled down to ensure there is no duplication with 






































between different companies or sectors, necessitating a sufficiently long period of 
transition before the benefits of such restructuring can be reaped. 
 
We cannot talk here of proximity, whether geographic or organisational, for the aim is 
of a totally different nature. On the other hand, the location of the firm plays an 
important role since it is often a Trojan horse enabling a bigger firm to penetrate a 





Based on a statistical analysis of the regional location and growth of biotech SMEs in 
France, this article considers the dynamics of localisation of firms when they set up, and 
the influence of geographic environment on their development. At the time of creation, 
geographic proximity with the initial networks of the entrepreneur (often from the 
public or private research community) impacts strongly on the firm’s location. 
Geographic proximity enables the firm to establish itself soundly in its local 
environment, and organisational and geographic proximity overlap. This is one of the 
reasons why the impact of regional public policy in favour of business creation is so 
strong. As the firm grows, organisational proximity dominates and the firm moves away 








































As in traditional sectors, certain elements influence biotech firms’ choice of locality. 
Local infrastructure (incubators, support activities, innovation missions, etc.) plays a 
key part in firms’ location. For some firms with technological needs that they cannot 
meet on their own, the existence of a technology platform is essential. For these firms, 
whose development is science-based, proximity with high-quality academic research is 
important. Such research provides a favourable cultural and scientific environment to 
attract able researchers likely to cooperate with the firm and thus enhance its scientific 
potential and reputation. 
 
Even if, in high-tech sectors with an international profile, the importance of geographic 
proximity decreases as the firm grows, localisation in a dynamic scientific environment 
suited to the emergence of new activities is essential at the time of creation. Regional 
policies thus have a strong impact on a firm’s initial location, simultaneously creating 
self-reinforcing effects on a given geographic area and clusters of firms. 
 
While policies in favour of business creation seem to combine harmoniously on the 
different levels of public intervention (municipal, regional and national), the problem of 
firms’ survival after two or three years is a very real one in an industry characterised by 
rapid technological change. Further studies will need to examine the development of 






































favour of start-ups and geographic spillovers). Others will also need to examine the 
linkages between the scientific reputation and the development of firms, by region. 
 
In France there is diversity in the modes of development of biotech SMEs, adapted to 
the projects of their directors and shareholders. The path of ‘success’, where the firm 
tries to grow as fast as possible and aims at becoming world leader in its sector and in 
the stock market, is not the only possible one for biotech firms. It is probable, however, 
that from their creation firms in the biotech sector prepare their future and growth 
trajectory which will depend on the amount of initial investments, the networks to 
which they have access, the partnerships they form and whether or not they choose to 
appeal to outside investors. Policies supporting innovation and high-tech SMEs have to 
take this into account, or they could set viable firms on paths that prove to be nothing 







































Box 7.1: Data collected by means of the questionnaire 
 
 
• Identity of the firm and the top managers, with position 
• Main technologies developed and implemented by the firm (to be ticked off on a list of 33 
   technologies) 
• Main areas of activity (markets) in which the firm is active (to be ticked off on a list of 28 markets) 
• Turnover, R&D spending, net and effective income for past three years 
• Patents owned and exploited by the firm 
• Quality control in the firm 
• Effective and hoped for partnerships for research, production and commercialisation. 
 
 
On the initiative of the MENRT Technology Division (Biotechnology group)
5 a survey 
was made of firms performing biotechnology research. Biotechnology firms were 
considered to be those that develop or use industrial technologies derived from life 
science and technology (and sometimes materials) using the properties of living 
organisms for producing goods and services (definition proposed by the Industry 
Ministry, ‘Les 100 technologies clés à l’horizon 2000’). 
The survey consisted of several stages: 
1.  Compilation of list of organisations (firms, economic interest groups, and 
associations) engaged in biotechnology research), from available sources. 






































3.  Definition of list of 478 target organisations, irrespective of size or status (SA, not 
for profit organisations). 
4.  Administration of the questionnaire. 
5.  Processing of data and compilation of a directory. 
221 answers were registered but remained largely incomplete. In order to obtain a 
representative sample, the data base thus obtained was enhanced with various other 
available data bases: base constituted by the INRA/SERD team, the France Biotech 
base, the Genetic Engineering Directory, Infogreffe and Diane. Missing information 
was thus obtained and certain firms were added to the base when all the required 
information was available. 
In order to standardise the answers, only registered companies (SA (Société 
Anonyme), SARL (Société Anonyme à Responsabilité Limitée), SNC (Société en 
Nom Collectif)) were selected. To ensure the relevance of comparisons with 
information published by Ernst & Young (1999 Report), we analysed only those firms 
with under 500 employees. Finally, we excluded the rare biotech firms created before 
1960. The base used in our analysis consisted of 194 firms, for which full information 
was available. Several indications allow us to consider the analysed sample as 
representative: over 60 per cent of the firms in the France Biotech directory and 90 per 
cent of the firms present in the Genetic Engineering Directory answered the 
questionnaire. When we analyse the base of 600 firms to which the questionnaire was 
sent, fewer than 450 corresponded to the selected criteria. We can therefore consider 
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4 This result was obtained for the 1990s by measuring the geography of public R&D 
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